Value of fRagmented Atrial electrOgrams, Computed Tomography and Intracardiac Echocardiography for Identification of optiMal Sites for Radio-frequency Delivery During cArdioneuroablation for Asystolic Reflex syNcope
Cardioneuroablation: Fragmented Atrial Potentials, Intracardiac Echocardiography and Computed Tomography
Sponsors
Source
Centre of Postgraduate Medical Education
Oversight Info
Has Dmc
No
Is Us Export
No
Is Fda Regulated Drug
No
Is Fda Regulated Device
No
Brief Summary
Cardioneuroablation (CNA) is a new method for the treatment of asystolic reflex syncope,
however, optimal methods for identification of presumed sites of ganglionated plexi (GP),
which are the target for CNA and are located in the epicardial fat, have not yet been
established. This study will compare the accuracy of three methods used for
identification of these areas: intracardiac recordings of fractionated atrial
electrograms, intracardiac echocardiography and computed tomography. The study group will
consist of 100 patients undergoing CNA in our institution. The procedure will be
performed in a standard manner with the use of extracardiac vagal stimulation as the
intraprocedural end-point. Correlation between the three methods used for localisation of
optimal sites for CNA as well as their predictive value for achieving effective CNA will
be computed.
Detailed Description
Cardioneuroablation (CNA) is a new method for the treatment of asystolic reflex syncope.
Although the procedure is becoming more and more popular, many important issues remain
unresolved. One such a problem is the optimal method for identification of presumed sites
of ganglionated plexi (GP) which are located in the epicardial fat surrounding myocardium
and are the target for CNA. Several methods have been used, including anatomical approach
using computed tomography (CT), intracardiac echocardiography (ICE) and 3D
electro-anatomical mapping (EAM) as well as electrophysiological methods which include
high-frequency stimulation and recording of fragmented atrial potentials (FP).
Areas of FAP are sought to represent nerve fibers endings, extending from GPs to
myocardium. The technique was first described by in 2004 and spectral analysis with fast
Fourier transformation was used to identify these areas. Next, the time-domain
quantification of FAP characteristics was performed. It was found that a high number of
deflections (at least 4) identified the presumed areas of GPs. Later on, this method was
further developed and it has been shown that FAP-guided CNA was associated with shorter
procedure and fluoroscopy times. The currently advocated approach is to evaluate FAP for
the number of deflections at filter settings of 200-500 Hz or 100-500 Hz. If ≥3
deflections are present, these sites are tagged as ablation targets.
However, the role of FAP for the identification of optimal sites for GPs ablation is
still debatable. Reproducibility of the results of spectral analysis of GPs areas has not
been well established. Also, sensitivity and specificity of both spectral and time-domain
analysis of FAP have not been established. The sensitivity of 72% and specificity of 91%
values were calculated for patients undergoing ablation for atrial fibrillation and not
CNA, were based on reflex bradycardia/asystole during RF delivery, mainly at posterior
left atrial (LA) wall and not by extra cardiac vagal stimulation (ECVS) after ablation at
typical sites for septal GPs. In fact, specificity may be limited because FAP may
represent areas of scarred atrial tissue, pulmonary vein (PV) potentials or fragmented
electrograms at such areas in the right atrium (RA) as slow pathway region, coronary
sinus (CS) os or RA-superior vena cava (SVC) junction. Moreover, the adipose tissue
surrounding the heart can infiltrate the atrial myocardium, causing heterogeneous
activation resulting in the presence of FAP. In addition, the sensitivity may also be
limited since effective RF applications, which cause total vagal denervation confirmed by
ECVS, can be sometimes performed at the areas with no FAP. To date, no study examined
prospectively and blindly characteristics of FAP in effective and non-effective sites,
confirmed by ECVS, in patients undergoing CNA due to reflex asystolic syncope.
Intracardiac echocardiography. This is another tool used for anatomical localisation of
presumed GP areas. With ICE, areas of epicardial fat in the so-called pyramidal space,
containing paraseptal inferior GP, as well as space between right superior PV (RSPV) and
SVC, containing superior paraseptal GP, can be visualised. The correlation between
ICE-identified areas of GPs and other tools like CT or FAP has not yet been established.
Computed tomography. Lastly, CT can be used during anatomical approach to identify target
sites for CNA. Current techniques enable visualisation of pericardial fat. Also, density
of the epicardial fat which may correspond to the density of GPs, can be quantified using
CT.
Whether the CT-, ICE- and FAB-based localisation of presumed GP's areas perfectly overlap
each over or there is a significant difference in their localisations, is not known.
Aims.
1. To assess the predictive value of FAP for identification of presumed areas of GPs
localisation.
2. To examine differences in FAP characteristics between superior and inferior
paraseptal GP's areas.
3. To assess the anatomical concordance between FAP-, ICE- and CT-based sites targeted
during CNA.
4. To describe the FAP, ICE and CT-based characteristics of the sites where vagal
denervation was achieved as assessed by ECVS.
Methods. Patients. The study group consists of consecutive patients undergoing CNA in our
institution. Patients are offered CNA if they have severe, recurrent symptoms due to
reflex syncope with ECG documented asystole >3 seconds, especially if associated with
injury, or recurrent presyncope with persistent reflex bradycardia. The patients have to
have a history of ineffective prior non-pharmacological treatment and positive baseline
atropine test (sinus rate acceleration > 30% and no AV block following 2 mg of
intravenous atropine). All patients gave informed written consent to undergo CNA and to
participate in the study (Research Grant CMKP #17/2024, Ethics Committee approval #
42/2024).
Cardioneuroablation. The procedure is performed under general anaesthesia with muscle
relaxation using a 3.5 mm irrigated tip catheter (Navistar ThermoCool SmartTouch) with
contact force module and electroanatomical mapping (EAM) system Carto 3 (Biosense
Webster, US). The ablation index is set at 500 except coronary sinus (CS) where the
target value is 350. Intracardiac echocardiography (ICE) (Acuson SC2000, Siemens,
Germany, AcuNav™ Ultrasound Catheter, Biosense Webster, US) is used throughout the whole
procedure and serves for guiding ablation, including identification of epicardial fat
tissue with presumed GP areas. Thus, the ICE images and EAM are used as "anatomical"
approach to perform CNA.
The ECVS is performed using two diagnostic catheters positioned in the right and left
jugular veins utilizing neurostimulator designed by Dr Pachon (Sao Paulo, Brazil) (pulse
amplitude of 1 V/kg body weight up to 70 V, 50 ms width, 50 Hz frequency, delivered over
5 sec). Complete bilateral vagal denervation of both sinus and AV nodes (no sinus arrest,
slowing of sinus rate no more than 10% compared with baseline and no AV block with PR
interval no longer than at baseline), documented on ECVS, is the end-point of CNA.
Ablation is started in LA at the anterior antrum of the right superior PV (RSPV) where
the superior paraseptal GP (SPSGP) is located, followed by ablation of the inferior
paraseptal GP (IPSGP) at the floor of LA. Next, these GPs are ablated from the RA. If the
intraprocedural endpoints of CNA are not achieved by ablation of paraseptal GPs,
additional applications in the LA at the sites of superior and postero-lateral LA GPs are
performed, followed by applications in the CS. The procedure is performed using pure
anatomical approach, based on ICE and EAM, and the operator is blinded to the CT and FAP
results. The amplitude of distal and proximal recordings from the ablation catheter are
truncated to zero and CT images, merged with the CARTO system at the beginning of the
procedure, are not displayed during CNA.
The ECVS is performed after each RF application to assess whether this specific burn
caused no vagal denervation (<10% change in sinus pause or AVB still present), partial
vagal denervation (10-90% shortening in sinus pause or lower degree of AVB still present)
or complete vagal denervation (>90% reduction of sinus pause duration and no AVB). If
after achieving complete vagal denervation additional consolidating RF applications are
performed, ECVS is not repeated and these sites are not taken in the analysis.
At the end of the procedure, atropine test is performed in order to assess the residual,
if present, vagal nerve activity. The value of < 10% of increase in sinus rate following
atropine injection (2 mg iv) is taken as complete vagal denervation. Regardless of the
results of this test, further RF applications are not performed and the procedure is
completed.
Fragmented electrogram recording and analysis. For the purpose of comparing FAB between
superior and inferior septal GP's, FAP are recorded at each site during constructing EAM
before starting RF applications. For the purpose of assessing predictive value of FAP
characteristics, FAP are recorded before each RF application (as previously described).
Bipolar endocardial potential recordings at each site of RF application are analysed at
an ECG speed of 400 mm/s and filter setting 100-500 Hz. Three FAP parameters are measured
- number of deflections, maximal amplitude and total FAP duration.
The measurements of the number of deflections are performed according to Aksu et al and
Lellouche et al. Number of deflections is assessed as the number of turning points
(positive to negative direction or vice versa) in each FAP. The FAP is defined as atrial
electrogram with > 3 deflections, however, other cut-off values for the number of
deflections are also tested.
The amplitude of FAP is measured in mV as the difference between the most negative and
the most positive deflection. The duration of FAP is measured in milliseconds from the
onset of the first deflection to the end of the last deflection.
All atrial electrograms are divided into (1) normal AP with ≤ 3 deflections; (2)
low-amplitude FAP with amplitude (difference between maximal positive and maximal
negative deflection) < 0.7 mV, and (3) high-amplitude FAP with amplitude ≥ 0.7 mV.
The analysis of FAP is performed off-line by an investigator who is blinded to the
procedural details, including which GP was ablated and what was the ECVS result after
each RF application. In order to overcome possible spontaneous variability of FAP
characteristics caused by electrode movements in a beating heart, the mean value of three
consecutive FAP recordings is taken as a final parameter.
Intra- and inter-observer variability of FAP measurements will be also assessed.
Computed tomography is performed using the Somatom go.Top (Siemens, Germany) tomograph.
After acquisition, the images are sent for further processing and reconstruction to the
inHeart platform. Acquisition will be performed according to the protocol used by the
inHeart. In brief, as many as possible complementary scans are acquired. In this
protocol, the acquisition is focused on the maximum filling volume of the atria. The
acquisition window is set on the systolic cardiac phase (200-400ms from R wave). The
amount of contrast and parameter settings are refined according to patient age and
possible renal failure. During the arterial phase the acquisition mode is prospective /
sequential. All the technical details are in the inHeart brochure.
When the CT reconstruction with the epicardial fat is received from the inHeart, it is
merged with the map obtained in the EAM system Carto-3. Care is taken to make the most
accurate matching, using right and left pulmonary artery, CS and ICE images as the anchor
points. Next, areas of presumed areas of GPs identified by ICE are marked on the EAM
using the CartoSound module (Biosense Webster, US). The ICE-based and CT-based areas with
epicardial fat are compared visually and also using the Carto system software which
enables calculation of the area and volume of a given structure. Also, visual correlation
between ICE-based RF applications points and localisation of epicardial fat areas imaged
by CT will be performed. As stated before, the identification of presumed GPs areas will
be based on ICE and EAM whereas CT images will be used after ablation to compare
ICE-based and CT-based localisations of epicardial fat and GPs.
Overall Status
Recruiting
Start Date
2024-05-20
Completion Date
2025-12-31
Primary Completion Date
2025-12-31
Phase
N/A
Study Type
Interventional
Primary Outcome
Measure |
Time Frame |
|
Predictive value of fragmented atrial potentials |
During procedure (2 hours) |
Secondary Outcome
Measure |
Time Frame |
|
Localization of presumed areas of ganglionated plexi |
During procedure (2 hours) |
|
Accuracy of identification of sites where effective cardioneuroablation was performed |
During procedure (2 hours) |
|
Number of deflections of fragmented atrial potentials at inferior and superior areas of ganglionated plexi |
During procedure (2 hours) |
|
Duration of fragmented atrial potentials at inferior and superior areas of ganglionated plexi |
During procedure (2 hours) |
|
Amplitude of fragmented atrial potentials at inferior and superior areas of ganglionated plexi |
During procedure (2 hours) |
Enrollment
100
Condition
Intervention
Intervention Type
Procedure
Intervention Name
Description
Endocardial radio-frequency ablation of areas of ganglionated plexi in the left and the
right atrium
Eligibility
Criteria
Inclusion Criteria:
- severe, recurrent symptoms due to reflex syncope with ECG documented asystole >3
seconds, especially if associated with injury, or recurrent presyncope with
persistent reflex bradycardia
- history of ineffective prior non-pharmacological treatment and positive baseline
atropine test (sinus rate acceleration > 30% and no AV block following 2 mg of
intravenous atropine) -
- informed written consent obtained
Exclusion Criteria:
- contraindications to perform cardioneuroablation
- contraindications to perform computed tomography with intravenous contrast injection
- lack of informed written consent obtained
Gender
All
Minimum Age
14 Years
Maximum Age
N/A
Healthy Volunteers
No
Overall Official
Last Name |
Role |
Affiliation |
|
Roman Piotrowski, MD PhD |
Study Director |
Department of Cardiology, Grochowski Hospital, Medical Centre for Postgraduate Education |
Overall Contact
Last Name
Piotr Kułakowski, MD PhD
Phone
+48 22 5152757
kulak@kkcmkp.pl
Location
Facility |
Status |
Contact |
|
Department of Cardiology, Postgraduate Medical School, Grochowski Hospital Warsaw 756135 Masovian Voivodeship 858787 04-073 Poland |
Recruiting |
Last Name: Piotr Kulakowski, MD PhD Phone: +48 22 51 52 757 Email: kulak@kkcmkp.pl |
Location Countries
Country
Poland
Verification Date
2025-09-01
Lastchanged Date
N/A
Firstreceived Date
N/A
Responsible Party
Responsible Party Type
Principal Investigator
Investigator Affiliation
Centre of Postgraduate Medical Education
Investigator Full Name
Prof. Piotr Kulakowski
Investigator Title
Professor
Keywords
Has Expanded Access
No
Condition Browse
Firstreceived Results Date
N/A
Overall Contact Backup
Last Name
Agnieszka Sikorska, MD PhD
Phone
+48 22 5152757
sikorska.agnieszka.anna@gmail.com
Reference
Citation
Pachon JC, Pachon EI, Pachon JC, Lobo TJ, Pachon MZ, Vargas RN, Jatene AD. "Cardioneuroablation"--new treatment for neurocardiogenic syncope, functional AV block and sinus dysfunction using catheter RF-ablation. Europace. 2005 Jan;7(1):1-13. doi: 10.1016/j.eupc.2004.10.003.
PMID
15670960
Citation
Lellouche N, Buch E, Celigoj A, Siegerman C, Cesario D, De Diego C, Mahajan A, Boyle NG, Wiener I, Garfinkel A, Shivkumar K. Functional characterization of atrial electrograms in sinus rhythm delineates sites of parasympathetic innervation in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 2007 Oct 2;50(14):1324-31. doi: 10.1016/j.jacc.2007.03.069. Epub 2007 Sep 17.
PMID
17903630
Citation
Aksu T, De Potter T, John L, Osorio J, Singh D, Alyesh D, Baysal E, Kumar K, Mikaeili J, Dal Forno A, Yalin K, Akdemir B, Woods CE, Salcedo J, Eftekharzadeh M, Akgun T, Sundaram S, Aras D, Tzou WS, Gopinathannair R, Winterfield J, Gupta D, Davila A. Procedural and short-term results of electroanatomic-mapping-guided ganglionated plexus ablation by first-time operators: A multicenter study. J Cardiovasc Electrophysiol. 2022 Jan;33(1):117-122. doi: 10.1111/jce.15278. Epub 2021 Oct 25.
PMID
34674347
Citation
Kulakowski P, Baran J, Sikorska A, Krynski T, Niedzwiedz M, Soszynska M, Piotrowski R. Cardioneuroablation for reflex asystolic syncope: Mid-term safety, efficacy, and patient's acceptance. Heart Rhythm. 2024 Mar;21(3):282-291. doi: 10.1016/j.hrthm.2023.11.022. Epub 2023 Nov 29.
PMID
38036236
Citation
Francia P, Viveros D, Falasconi G, Soto-Iglesias D, Fernandez-Armenta J, Penela D, Berruezo A. Computed tomography-based identification of ganglionated plexi to guide cardioneuroablation for vasovagal syncope. Europace. 2023 Jun 2;25(6):euad170. doi: 10.1093/europace/euad170.
PMID
37343139
Acronym
Roman5
Patient Data
Sharing Ipd
Yes
Ipd Description
To share with other investigators study details upon reasonable requests
Ipd Info Type
Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Ipd Time Frame
From December 2025 to December 2027
Ipd Access Criteria
e-mail contacts
Firstreceived Results Disposition Date
N/A
Study Design Info
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)
Study First Submitted
June 15, 2024
Study First Submitted Qc
June 22, 2024
Study First Posted
June 24, 2024
Last Update Submitted
September 23, 2025
Last Update Submitted Qc
September 23, 2025
Last Update Posted
September 26, 2025
ClinicalTrials.gov processed this data on November 26, 2025
Conditions
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Interventions
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Study Phase
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.

